|
Users
|
|
Any user
|
6.6 (4.2–9.3)
|
113.8 (74.1–183.2)
| |
|
Pharmacists
|
5.9 (3.3–8.2)
|
104.7 (51.2–136.0)
| |
|
Practice staff
|
0.5 (0.0–1.5)
|
5.3 (0.0–27.6)
| |
|
Time
|
|
First quarter
|
12.0 (5.0–15.2)
|
217.4 (108.4–319.6)
| |
|
Second quarter
|
4.5 (2.8–7.4)
|
69.6 (37.7–102.8)
| |
|
Third quarter
|
6.3 (3.7–10.2)
|
90.4 (50.0–172.2)
| |
|
Fourth quarter
|
5.7 (2.7–9.3)
|
88.4 (27.4–155.9)
| |
|
Dashboard pages
|
|
Practice summary
|
9.1 (5.3–14.2)
|
181.5 (66.9–289.0)
| |
|
Table overview
|
18.4 (12.2–28.9)
|
765.9 (380.6–1132.9)
| |
|
Chart overview
|
0.9 (0.4–3.0)
|
25.2 (4.6–119.2)
| |
|
Indicator information
|
0.5 (0.2–1.0)
|
67.0 (4.5–228.8)
| |
|
Patient list (any medication safety indicator)
|
19.3 (14.1–35.6)
|
2907 (1722.0–5371.3)
|
67 (45–128.5)
|
|
Patient lists for specific types of medication safety risks
|
|
1. Prescription of an oral NSAID without co-prescription of an ulcer-healing drug in a patient aged ≥65 years
|
4.4 (2.5–9.0)
|
747.9 (338.9–1307.8)
|
26 (11.5–42.5)
|
|
2. Prescription of an oral NSAID without co-prescription of an ulcer-healing drug to a patient with a history of peptic ulceration
|
0.3 (0.1–1.0)
|
13.1 (0.4–92.2)
|
1 (1–3)
|
|
3. Prescription of an antiplatelet drug without co-prescription of an ulcer-healing drug to a patient with a history of peptic ulceration
|
2.0 (0.5–2.8)
|
224.4 (98.1–456.4)
|
4 (2–6.5)
|
|
4. Prescription of warfarin or NOAC in combination with an oral NSAID
|
1.3 (0.5–1.9)
|
98.7 (39.3–211.7)
|
4 (2–6)
|
|
5. Prescription of warfarin or NOAC in combination with an antiplatelet drug without co-prescription of an ulcer-healing drug
|
1.3 (0.8–2.5)
|
130.3 (77.5–358.2)
|
4 (2–9)
|
|
6. Prescription of an aspirin in combination with another antiplatelet drug without co-prescription of an ulcer-healing drug
|
2.5 (1.1–3.8)
|
345.5 (142.6–532.6)
|
8 (5–13)
|
|
7. Prescription of a non-selective beta-blocker to a patient with asthma
|
3.8 (2.0–5.5)
|
600.3 (358.0–914.2)
|
15 (8–28.5)
|
|
8. Prescription of a long-acting beta-2 inhaler (excluding combination products with inhaled corticosteroid) to a patient with asthma who is not also prescribed an inhaled corticosteroid
|
0.8 (0.0–1.7)
|
65.2 (0.0–188.6)
|
2 (0–6)
|
|
9. Prescription of an oral NSAID to a patient with heart failure
|
0.8 (0.3–1.8)
|
50.9 (5.5–123.0)
|
2 (1–5)
|
|
10. Prescription of an oral NSAID to a patient with chronic renal failure (eGFR< 45)
|
0.5 (0.2–1.3)
|
55.7 (0.8–114.8)
|
3 (1.5–5)
|
|
11. Prescription of methotrexate without both a recent full blood count and a recent liver function test
|
1.2 (0.7–2.3)
|
158.2 (70.3–315.1)
|
4 (2.5–6)
|
|
12. Prescription of amiodarone without a thyroid function test
|
1.5 (0.8–3.3)
|
191.7 (40.3–358.3)
|
4 (2–6)
|
|
Multiple medication safety indicators
|
0.3 (0.1–0.7)
|
17.5 (0.8–158.0)
|
4 (2–7)
|
